Page 6,452«..1020..6,4516,4526,4536,454..6,4606,470..»

UNE gets $50K to expand pharmacy opportunities for grads

Posted: Published on October 2nd, 2012

Posted: 12:15 PM Updated: 2:58 PM The College of Pharmacy will graduate its inaugural class next spring. By Gillian Graham ggraham@mainetoday.com Staff Writer The University of New England's College of Pharmacy was awarded a $50,000 grant to expand community pharmacy opportunities for graduates. The grant was awarded by the NationalAssociation of Chain Drug Stores Foundation. The College of Pharmacy will graduate its inaugural class next spring. "This grant will allow for the expansion of community pharmacy practice services within the state of Maine and across the country. This is a unique opportunity to place a focus on the efforts and abilities of community pharmacists as the profession of pharmacy continues to grow, said Meghan Sullivan, the grant recipient and Community Pharmacy Residency Program director. UNEs practice site for the grant is Martins Point Health Care, a nonprofit organization based in Portland. This is an incredibly exciting opportunity for Martins Point to partner with UNE to help advance the profession of pharmacy in the state of Maine, Rebekah Dube, Martins Point Health Cares director of Medicare and pharmacy program management, said in a prepared statement. Pharmacists play an integral role in the health care team and this residency will provide a … Continue reading →

Posted in Pharmacy | Comments Off on UNE gets $50K to expand pharmacy opportunities for grads

CVS/pharmacy(R) Joins the Millions(R) in the Movement to Stop Diabetes(R)

Posted: Published on October 2nd, 2012

ALEXANDRIA, VA--(Marketwire - Oct 1, 2012) - The American Diabetes Association announced today that this November's American Diabetes Month is sponsored by the CVS/pharmacy ExtraCare Advantage for Diabetes savings program, afree offering that provides exclusive savings, prescription management services, recipes,and pharmacist tips developed exclusively for those living with the disease as well as their caregivers. Starting on Oct. 1, 2012, the Association will be asking the public to become part of the movement to Stop Diabetes by sharing a personal image on the Association's main Facebook page representing whatA Day in the Life of Diabetes means to them. The image can be a picture of themselves or someone they care about, or otherwise represent how the disease impacts their lives.Successfully managing diabetes can be a herculean task, making what might seem like an otherwise ordinary life rather extraordinary. Using imagery, the power of social engagement and a larger-than-life stage, light will be shed on the issue of diabetes and those who live with it each and every day. To encourage individuals to share photos of A Day in the Life of Diabetes on Facebook, CVS/pharmacy will donate $1 to the American Diabetes Association for every photo/image uploaded, up to $25,000. … Continue reading →

Posted in Pharmacy | Comments Off on CVS/pharmacy(R) Joins the Millions(R) in the Movement to Stop Diabetes(R)

Houston Stem Cell Summit Announces Extraordinary Lineup of Keynote Speakers

Posted: Published on October 2nd, 2012

HOUSTON, Oct. 1, 2012 /PRNewswire/ --The Houston Stem Cell Summit will host an extraordinary lineup of keynote speakers who represent the most accomplished stem cell scientists, clinicians and entrepreneurs in the United States. Joining these distinguished speakers will be Governor of Texas, Rick Perry, consistent champion of adult stem cell therapies. (Logo: http://photos.prnewswire.com/prnh/20120831/NY66463LOGO ) The Houston Stem Cell Summit will be held October 26 27 in its namesake city and will highlight the latest therapeutic research regarding the use of adult stem and progenitor cell therapies. The Summit will also provide a forum for entrepreneurs to discuss their latest efforts to commercialize stem cell therapies, and to debate and discuss FDA and other legal and regulatory issues impacting stem cell research and commercialization. Opening Keynote Address October 26, 2012 Arnold I. Caplan, PhD, Professor of Biology and Professor of General Medical Sciences (Oncology) Case Western Reserve University Dr. Caplan has helped shape the direction and focus of adult stem cell research and commercialization. Virtually every adult stem cell company and literally tens of thousands of research papers are based on Dr. Caplan's original and ground breaking research. Professor Caplan is considered to be the "father" of the mesenchymal stem cell … Continue reading →

Comments Off on Houston Stem Cell Summit Announces Extraordinary Lineup of Keynote Speakers

Experimental Stem Cell Therapy May Help Burn Victims

Posted: Published on October 2nd, 2012

For more than 40 years, Lesley Kelly of Glasgow, Scotland, lived with third-degree burns that stretched over 60 percent of her body. Kelly was 2 years old when she fell into a bathtub filled with hot water that scorched most of the right side of her body. She lost full range of motion around many of her joints. "When you have bad scarring, the buildup is very thick and has no elasticity," said Kelly, 45, whose right elbow was most affected by the buildup of scar tissue. "The problem with thermal burn scarring [is that] it's hard to get the range of motion." Kelly underwent numerous reparative surgeries through the years, but the scar tissue continued to grow back. The procedures did not lessen the look of her scars. In 2011, Kelly underwent a new, experimental procedure that used stem cells from her own fat tissue to repair the buildup around her right elbow. Surgeons cleaned the scar buildup around the elbow and used liposuction to pull fat from off Kelly's waist. They separated the fat cells from the stem and regenerative cells, which were then injected into the wound on Kelly's arm. The procedure took less than two hours. … Continue reading →

Comments Off on Experimental Stem Cell Therapy May Help Burn Victims

New Therapy May Help Burn Victims

Posted: Published on October 2nd, 2012

Lesley Kelly, 45, underwent stem cell therapy to repair scar tissue buildup in her right arm. (Cytori Therapeutics, Inc.) By Lara Salahi, ABC News For more than 40 years, Lesley Kelly of Glasgow, Scotland, lived with third-degree burns that stretched over 60 percent of her body. Kelly was 2 years old when she fell into a bathtub filled with hot water that scorched most of the right side of her body. She lost full range of motion around many of her joints. "When you have bad scarring, the buildup is very thick and has no elasticity," said Kelly, 45, whose right elbow was most affected by the buildup of scar tissue. "The problem with thermal burn scarring [is that] it's hard to get the range of motion." Kelly underwent numerous reparative surgeries through the years, but the scar tissue continued to grow back. The procedures did not lessen the look of her scars. In 2011, Kelly underwent a new, experimental procedure that used stem cells from her own fat tissue to repair the buildup around her right elbow. Surgeons cleaned the scar buildup around the elbow and used liposuction to pull fat from off Kelly's waist. They separated the fat … Continue reading →

Comments Off on New Therapy May Help Burn Victims

Health Link Medical Center Introduces the Regenexx™ Orthopedic Stem Cell Treatments to the San Francisco Area

Posted: Published on October 2nd, 2012

OCEANSIDE, Calif., Oct. 1, 2012 /PRNewswire/ --Health Link Medical Center, a national leader in regenerative interventional orthopedics and advanced biological cell therapies, today announced the planned opening of their new location in Mill Valley, California in October 2012. Health Link Medical Center's Oceanside, California clinic is currently California's only provider of Regenexx orthopedic platelet and autologous stem cell procedures. Regenexx Procedures offer non-surgical treatment options for common joint injuries and degenerative conditions, such as osteoarthritis. The procedures utilize a patient's own stem cells to help heal damaged tissues, tendons, ligaments, bone, or cartilage. Regenexx patients experience less downtime and avoid the lengthy and painful rehabilitation periods that follow surgery. "We're excited for the opportunity to bring Regenexx Procedures to the San Francisco area," said Dr. Norman Deitch, CEO of Health Link Medical Center. "Patients regularly travel across the country for the opportunity to receive these leading non-surgical treatments. This expansion makes them conveniently accessible to the millions of individuals in northern California." The Mill Valley Center will include a biological cell laboratory, capable of the advanced laboratory processing of platelets and stem cells required for the same-day procedures. Paul Handleman, D.O., has joined Health Link with an extensive interventional orthopedic … Continue reading →

Posted in Stem Cell Treatments | Comments Off on Health Link Medical Center Introduces the Regenexx™ Orthopedic Stem Cell Treatments to the San Francisco Area

Translational Regenerative Medicine: Market Prospects 2012-2022

Posted: Published on October 2nd, 2012

NEW YORK, Oct. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Translational Regenerative Medicine: Market Prospects 2012-2022 http://www.reportlinker.com/p0595030/Translational-Regenerative-Medicine-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation Report Details New study shows you commercial potential of regenerative treatments See what the future holds for translational regenerative medicine. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product and regional level to 2022. There you investigate the most lucrative areas in that research field, industry and market. Discover prospects for tissue-engineered products, stem cell treatments and gene therapy. We pack our study with information and analysis to help your work and save you time: Access to present and predicted trends, with commercial opportunities and prospects revealed Data and discussions - including our revenue forecasts to 2022 - for your research, analyses and decision making Read this article: Translational Regenerative Medicine: Market Prospects 2012-2022 … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Translational Regenerative Medicine: Market Prospects 2012-2022

Medistem and Superview Biotechnology Co. Ltd. Initiate Collaboration on Therapeutics Development Using Antibody and …

Posted: Published on October 2nd, 2012

SAN DIEGO--(BUSINESS WIRE)-- Medistem Inc (Pink Sheets:MEDS) announced today the initiation of a collaboration with Superview Biotechnology Co. Ltd, a subsidiary of Yinhuan Holding Co from Yixing, China. The joint work will be aimed at using proprietary stem cell lines developed by Medistem for screening of monoclonal antibodies for therapeutic activity in the area of regenerative medicine. As part of the collaboration, the two companies will evaluate various candidates jointly, as well as apply for grants and share research data. To date, the majority of stem cell companies are focusing on the stem cell itself being a product. By collaborating with Superview Biotechnology, we aim to assess the feasibility of developing antibodies that can modulate the activity of stem cells that already exist in the body, said Thomas Ichim, CEO of Medistem. This approach not only provides methods of activating stem cells but also allows for the development of stem cell adjuvant therapies that could be used to resurrect stem cell candidates that failed in clinical trials. Superview Biotechnology has developed proprietary methods of rapidly generating monoclonal antibodies to esoteric protein targets. Medistem has a history of success in the area of stem cells, being the only company to take … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Medistem and Superview Biotechnology Co. Ltd. Initiate Collaboration on Therapeutics Development Using Antibody and …

Celltex To Initiate New Clinical Program As It Responds To FDA Letter

Posted: Published on October 2nd, 2012

HOUSTON, Oct. 1, 2012 /PRNewswire/ --Celltex Therapeutics Corp. announced today that it has received a letter, dated Sept. 24, 2012, from the U.S. Food and Drug Administration. The letter stated the agency's opinion that the process Celltex uses to multiply adult stem cells is subject to FDA regulation as biological drug manufacturing. The issue is a key one as stem cell therapy for patient care outside of an academic institution is a new frontier, yet there are a variety of technologies being used throughout the United States, often creating complex legal and regulatory questions. David Eller, CEO and President of Celltex, stated: Celltex makes identical copies of an individual's own stem cells and therefore should not be subject to FDA regulation as drugs. However, the FDA said our process causes the cells to be considered biological drugs and thus is subject to those regulations. We respectfully but firmly disagree with the FDA and intend to contest the agency's opinion within its administrative procedures. We are considering all options as we work with the agency toward a resolution. FDA's letter also repeats its earlier observations from an April inspection of Celltex's laboratory. While Celltex provided detailed responses in April, May, June, … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Celltex To Initiate New Clinical Program As It Responds To FDA Letter

RBCC: Could Stem Cells Hold the Key to Treating Traumatic Brain Injuries?

Posted: Published on October 2nd, 2012

NOKOMIS, Fla.--(BUSINESS WIRE)-- As part of Rainbow Coral Corp.s mission to deliver effective new cures for traumatic brain injury, the company is investigating promising research on the potential of stem cell therapy to improve the lives of millions suffering from the affliction. Scientists within the U.S. medical community have begun to see positive results from the treatment of patients with traumatic brain injury (TBI) through the use of stem cells. Significant improvements are seen between three to six months after treatment in brain injury patients. RBCC is working hard to capitalize on the growing demand for effective treatments for TBI, Parkinsons and other neurological health issues. RBCC is continuing discussions with the license holders for a NASA-developed bioreactor that assists in the expansion of adult stem cells. Such treatments could give RBCC access to markets in excess of $100 billion. Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ:AMGN),Cell Therapeutics, Inc. (CTIC), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY). For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors. Follow us on Twitter atwww.twitter.com/RBCCinfo. About Rainbow BioSciences Rainbow BioSciences is a division ofRainbow Coral Corp.(OTCBB:RBCC). The company continually seeks out new … Continue reading →

Comments Off on RBCC: Could Stem Cells Hold the Key to Treating Traumatic Brain Injuries?

Page 6,452«..1020..6,4516,4526,4536,454..6,4606,470..»